View Item 

Show simple item record

Muir‐Torre syndrome appropriate use criteria: Effect of patient age on appropriate use scores
dc.contributor.authorVidal, Claudia I.
dc.contributor.authorSutton, Angela
dc.contributor.authorArmbrect, Eric A.
dc.contributor.authorLee, Jason B.
dc.contributor.authorLitzner, Brandon R.
dc.contributor.authorHurley, M. Yadira
dc.contributor.authorAlam, Murad
dc.contributor.authorDuncan, Lyn M.
dc.contributor.authorElston, Dirk M.
dc.contributor.authorEmanuel, Patrick O.
dc.contributor.authorFerringer, Tammie
dc.contributor.authorFung, Maxwell A.
dc.contributor.authorHosler, Gregory A.
dc.contributor.authorLazar, Alexander J.
dc.contributor.authorLowe, Lori
dc.contributor.authorPlaza, Jose A.
dc.contributor.authorRobinson, June K.
dc.contributor.authorSchaffer, Andras
dc.date.accessioned2019-08-09T17:12:50Z
dc.date.availableWITHHELD_12_MONTHS
dc.date.available2019-08-09T17:12:50Z
dc.date.issued2019-07
dc.identifier.citationVidal, Claudia I.; Sutton, Angela; Armbrect, Eric A.; Lee, Jason B.; Litzner, Brandon R.; Hurley, M. Yadira; Alam, Murad; Duncan, Lyn M.; Elston, Dirk M.; Emanuel, Patrick O.; Ferringer, Tammie; Fung, Maxwell A.; Hosler, Gregory A.; Lazar, Alexander J.; Lowe, Lori; Plaza, Jose A.; Robinson, June K.; Schaffer, Andras (2019). "Muir‐Torre syndrome appropriate use criteria: Effect of patient age on appropriate use scores." Journal of Cutaneous Pathology 46(7): 484-489.
dc.identifier.issn0303-6987
dc.identifier.issn1600-0560
dc.identifier.urihttps://hdl.handle.net/2027.42/150503
dc.publisherWiley Periodicals, Inc.
dc.publisherBlackwell Publishing Ltd
dc.subject.otheranatomic location
dc.subject.otherappropriate use criteria
dc.subject.otherexpert rating
dc.subject.otherimmunohistochemistry
dc.subject.othermismatch repair protein analysis
dc.subject.otherMuir‐Torre syndrome
dc.subject.otherpatient age
dc.subject.othersebaceous neoplasms
dc.titleMuir‐Torre syndrome appropriate use criteria: Effect of patient age on appropriate use scores
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelDermatology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/150503/1/cup13459_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/150503/2/cup13459.pdf
dc.identifier.doi10.1111/cup.13459
dc.identifier.sourceJournal of Cutaneous Pathology
dc.identifier.citedreferenceVidal CI, Armbrect EA, Andea AA, et al. Appropriate use criteria in dermatopathology: initial recommendations from the American Society of Dermatopathology. J Am Acad Dermatol. 2018; 80 ( 1 ): 189 – 207.
dc.identifier.citedreferenceVidal CI, Armbrect EA, Andea AA, et al. Appropriate use criteria in dermatopathology: initial recommendations from the American Society of Dermatopathology. J Cutan Pathol. 2018; 45 ( 8 ): 563 ‐ 580.
dc.identifier.citedreferenceLee JB, Litzner BR, Vidal CI. Review of the current medical literature and assessment of current utilization patterns regarding mismatch repair protein immunohistochemistry in cutaneous Muir‐Torre syndrome‐associated neoplasms. J Cutan Pathol. 2017; 44 ( 11 ): 931 ‐ 937.
dc.identifier.citedreferenceJohn AM, Schwartz RA. Muir‐Torre syndrome (MTS): an update and approach to diagnosis and management. J Am Acad Dermatol. 2016; 74 ( 3 ): 558 ‐ 566.
dc.identifier.citedreferenceAbbas O, Mahalingam M. Cutaneous sebaceous neoplasms as markers of Muir‐Torre syndrome: a diagnostic algorithm. J Cutan Pathol. 2009; 36 ( 6 ): 613 ‐ 619.
dc.identifier.citedreferenceMachin P, Catasus L, Pons C. Microsatellite instability and immunostaining for MSH‐2 and MLH‐1 in cutaneous and internal tumors from patients with the Muir‐Torre syndrome. J Cutan Pathol. 2002; 29 ( 7 ): 415 ‐ 420.
dc.identifier.citedreferenceLynch HT, Lynch PM, Pester J, Fusaro RM. The cancer family syndrome. Rare cutaneous phenotypic linkage of Torre’s syndrome. Arch Intern Med. 1981; 141 ( 5 ): 607 ‐ 611.
dc.identifier.citedreferenceMuir EG, Bell AJ, Barlow KA. Multiple primary carcinomata of the colon, duodenum, and larynx associated with kerato‐acanthomata of the face. Br J Surg. 1967; 54 ( 3 ): 191 ‐ 195.
dc.identifier.citedreferenceTorre D. Multiple sebaceous tumors. Arch Dermatol. 1968; 98 ( 5 ): 549 ‐ 551.
dc.identifier.citedreferenceOrr CK, Yazdanie F, Shinder R. Current review of sebaceous cell carcinoma. Curr Opin Ophthalmol. 2018; 29 ( 5 ): 445 ‐ 450.
dc.identifier.citedreferenceNorth JP, Golovato J, Vaske CJ, et al. Cell of origin and mutation pattern define three clinically distinct classes of sebaceous carcinoma. Nat Commun. 2018; 9 ( 1 ): 1894.
dc.identifier.citedreferenceTetzlaff MT, Singh RR, Seviour EG, et al. Next‐generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma. J Pathol. 2016; 240 ( 1 ): 84 ‐ 95.
dc.identifier.citedreferenceJessup CJ, Redston M, Tilton E, Reimann JD. Importance of universal mismatch repair protein immunohistochemistry in patients with sebaceous neoplasia as an initial screening tool for Muir‐Torre syndrome. Hum Pathol. 2016; 49: 1 ‐ 9.
dc.identifier.citedreferenceSingh RS, Grayson W, Redston M, et al. Site and tumor type predicts DNA mismatch repair status in cutaneous sebaceous neoplasia. Am J Surg Pathol. 2008; 32 ( 6 ): 936 ‐ 942.
dc.identifier.citedreferenceRoberts ME, Riegert‐Johnson DL, Thomas BC, et al. Screening for Muir‐Torre syndrome using mismatch repair protein immunohistochemistry of sebaceous neoplasms. J Genet Couns. 2013; 22 ( 3 ): 393 ‐ 405.
dc.identifier.citedreferenceRoberts ME, Riegert‐Johnson DL, Thomas BC, et al. A clinical scoring system to identify patients with sebaceous neoplasms at risk for the Muir‐Torre variant of Lynch syndrome. Genet Med. 2014; 16 ( 9 ): 711 ‐ 716.
dc.identifier.citedreferenceBhaijee F, Brown AS. Muir‐Torre syndrome. Arch Pathol Lab Med. 2014; 138 ( 12 ): 1685 ‐ 1689.
dc.identifier.citedreferenceFitch K, Bernstein S, Aguilar MS, et al. The RAND/UCLA Appropriateness Method User’s Manual 2001. No. MR‐1269‐DG‐XII/RE:126. Santa Monica, CA: RAND Corp.; 2001.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cup13459_am.pdf
Size:
348.8KB
Format:
PDF
View/Open
Name:
cup13459.pdf
Size:
1.061MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.